Welcome
Support Centre
17 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
An assessment of the effects of altering blood pressure on cerebral and systemic haemodynamics in patients with acute ischaemic stroke
ISRCTN ISRCTN19958964
ClinicalTrials.gov identifier
Public title An assessment of the effects of altering blood pressure on cerebral and systemic haemodynamics in patients with acute ischaemic stroke
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis To assess the effects of altering blood pressure on cerebral and systemic haemodynamics in patients with acute ischaemic stroke.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Ischaemic Stroke
Participants - inclusion criteria 1. Patients of either sex ≥18 years
2. Proven ischaemic stroke on computed tomography (CT)
3. Stroke onset within 96 hours
4. Written informed consent
Participants - exclusion criteria 1. Non-ischaemic stroke
2. Unconscious or Scandinavian Neurological Stroke Scale (SNSS) conscious level <4
3. Baseline systolic blood pressure (BP) >180 mmHg or <100 mmHg
4. Baseline diastolic BP >110 mmHg or <60 mmHg
5. Women of childbearing potential/pregnant/lactating
Anticipated start date 01/01/2000
Anticipated end date 01/01/2007
Status of trial Completed
Patient information material
Target number of participants 24
Interventions Patients will be randomised to receive intravenous dobutamine or normal saline alone. Dobutamine will be administered at increasing concentrations at 5 minute intervals. Measurements using transcranial doppler, pulse wave analysis and venous blood samples will be taken at baseline and at each 5 minute dose increment.
Primary outcome measure(s) The ability of dobutamine to reduce systolic, diastolic and mean arterial BP. Safety and tolerability of dobutamine in acute ischaemic stroke.
Secondary outcome measure(s) 90 day modified Rankin, Barthel and mortality.
Sources of funding University of Nottingham (UK) - Division of Stroke Medicine
Trial website
Publications
Contact name Prof  Philip  Bath
  Address Division of Stroke Medicine
Clinical Sciences Building
City Hospital Campus
Hucknall Road
  City/town Nottingham
  Zip/Postcode NG5 1PB
  Country United Kingdom
  Tel +44 (0)115 840 4792
  Email philip.bath@nottingham.ac.uk
Sponsor University of Nottingham (UK)
  Address Clinical Sciences Building
City Hospital Campus
Hucknall Road
  City/town Nottingham
  Zip/Postcode NG5 1PB
  Country United Kingdom
  Tel +44 (0)115 840 4791
  Fax +44 (0)115 840 4790
  Email phillip.bath@nottingham.ac.uk
Date applied 25/08/2005
Last edited 17/09/2009
Date ISRCTN assigned 28/10/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central